Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

ILLUMINATE-301 : A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Male or<br/>FemaleGender Male or

Closed (no longer recruiting)Status Closed (no longer recruiting)

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

ThreePhase Three

18+Age Over 18

Skin<br/>CancersCancer LocationSkin

Systemic therapy | SkinMelanoma (Skin)

Trial Overview Read MoreRead more

This phase III trial is comparing the effectiveness of an immunotherapy drug (Ipilimumab) with and without an injection of IMO-2125 within the tumour of patients who have advanced melanoma that has gotten worse on prior immunotherapy treatment.

This trial is treating patients with Melanoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Commercial Sponsor

Idera Pharmaceuticals, Inc.


In this trial, participants will be randomised into one of two arms of treatment. In Arm A, participants will receive four 3mg/kg doses of Ipilimumab intravenously over 90 minutes in Weeks 1, 4, 7 and 10. In Arm B, participants will receive the Arm A treatment plus an IMO intratumoral injection administered as 9 doses in Weeks 1, 2, 3, 5, 8, 11, 16, 20 and 24.

Not Recruiting Hospitals Read MoreRead more


Box Hill Hospital Medical Oncology
Box Hill
Lauren Mitchell
03 9094 9544

Barwon Health, University Hospital Geelong
Oncology Team

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.